Avid Bioservices Selected by Mapp Biopharmaceutical, Inc. for Clinical Development of Novel Human Monoclonal Antiviral Antibody
August 26, 2020 08:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2021 After Market Close on September 1, 2020
August 25, 2020 16:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Avid Bioservices Selected By Iovance Biotherapeutics to Lead Process Development Through CGMP Manufacturing of Novel IL-2 Analog, IOV-3001
August 06, 2020 08:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Avid Bioservices and Argonaut Manufacturing Services Enter Agreement to Offer Biotechnology and Pharmaceutical Clients Integrated Process Development, Drug Substance Manufacturing and Drug Product Parenteral Manufacturing
July 28, 2020 08:05 ET
|
Avid Bioservices, Inc; Argonaut Manufacturing Services
TUSTIN, Calif. and CARLSBAD, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing...
Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2020 and Recent Developments
June 30, 2020 16:05 ET
|
Avid Bioservices, Inc
-- Appointed Nicholas Green as President and Chief Executive Officer -- -- Recorded Fourth Quarter Revenue of $12.6 Million and Annual Revenue of $59.7 Million -- -- Signed $23 Million in Business...
Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2020 After Market Close on June 30, 2020
June 23, 2020 16:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Avid Bioservices Names Nicholas Green as President and Chief Executive Officer
June 23, 2020 08:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
June 03, 2020 16:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., June 03, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Avid Bioservices and Aragen Bioscience Enter Agreement to Offer Biotechnology and Pharmaceutical Clients Integrated Solution for Cell Line and Process Development through Commercial Manufacturing
May 06, 2020 08:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif. and MORGAN HILL, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing...
Avid Bioservices Announces Appointment of Two Senior Directors of Business Development with Responsibility for North America, Europe and Asia
April 13, 2020 08:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., April 13, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...